Boehringer’s HERNEXEOS® Approved in China as First Oral Targeted Therapy for Previously Treated Patients with HER2-Mutant Advanced NSCLC

Boehringer's HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71%...

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated ...

This press release is not intended for UK and US media.

Boehringer Ingelheim secures NMPA approval for HERNEXEOS® in HER2-mutant NSCLC with 71% response rate in Beamion-LUNG 1

Open the article to view the coverage from EuropaWire.eu

Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media.  HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial1 Zongertinib recently received Breakthrough Therapy Designation for the first-line treatment of advanced HER2-mutant NSCLC by the Center for Drug Evaluation (CDE) Boehringer […] The post Boehringers HERNEXEOS approved in China as first o…